Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HOTH NASDAQ:JAGX NASDAQ:MLND NASDAQ:NEOS NASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHOTHHoth Therapeutics$1.40-2.4%$1.10$0.58▼$3.80$18.43M0.673.71 million shs118,269 shsJAGXJaguar Animal Health$2.41+0.6%$4.48$2.28▼$110.75$2.45M0.5656,561 shs25,175 shsMLNDMillendo Therapeutics$6.90-0.7%$4.00$0.92▼$16.95$131.40M0.481.52 million shs42,293 shsNEOSNeos Therapeutics$1.15$1.06$0.45▼$1.68$57.22M1.57.44 million shs15.01 million shsTNXPTonix Pharmaceuticals$46.32+8.3%$32.58$6.76▼$130.00$334.01M2.05972,805 shs650,138 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHOTHHoth Therapeutics-0.69%+21.19%+10.00%+77.33%+60.67%JAGXJaguar Animal Health-11.48%-5.91%-31.52%-53.23%-97.65%MLNDMillendo Therapeutics0.00%-2.52%+5.14%-0.14%+211.66%NEOSNeos Therapeutics0.00%0.00%0.00%0.00%0.00%TNXPTonix Pharmaceuticals+4.67%+20.71%+33.77%+151.65%-28.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHOTHHoth Therapeutics3.1491 of 5 stars3.65.00.00.03.30.00.6JAGXJaguar Animal Health2.7217 of 5 stars3.55.00.00.02.20.00.6MLNDMillendo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANEOSNeos TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATNXPTonix Pharmaceuticals2.6636 of 5 stars3.52.00.00.01.73.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHOTHHoth Therapeutics 3.25Buy$4.00179.72% UpsideJAGXJaguar Animal Health 3.00Buy$60.002,410.46% UpsideMLNDMillendo Therapeutics 0.00N/AN/AN/ANEOSNeos Therapeutics 0.00N/AN/AN/ATNXPTonix Pharmaceuticals 3.00Buy$585.001,267.46% UpsideCurrent Analyst Ratings BreakdownLatest JAGX, MLND, HOTH, TNXP, and NEOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.006/12/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.006/3/2025TNXPTonix PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/19/2025JAGXJaguar Animal HealthFirst BerlinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.004/15/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHOTHHoth TherapeuticsN/AN/AN/AN/A$0.86 per shareN/AJAGXJaguar Animal Health$11.69M0.21N/AN/A$12.29 per share0.19MLNDMillendo TherapeuticsN/AN/AN/AN/A$1.78 per shareN/ANEOSNeos Therapeutics$64.65M0.89N/AN/A($0.12) per share-9.58TNXPTonix Pharmaceuticals$10.04M31.34N/AN/A$31.82 per share1.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHOTHHoth Therapeutics-$8.19M-$1.14N/AN/AN/AN/A-109.18%-100.22%8/8/2025 (Estimated)JAGXJaguar Animal Health-$38.49MN/A0.00N/AN/A-343.92%-432.91%-71.25%8/12/2025 (Estimated)MLNDMillendo Therapeutics-$36.41MN/A0.00∞N/AN/A-91.03%-72.44%N/ANEOSNeos Therapeutics-$16.90M-$0.34N/AN/AN/A-38.35%N/A-28.46%N/ATNXPTonix Pharmaceuticals-$130.04M-$1,963.61N/AN/AN/A-1,313.87%-120.96%-101.28%8/15/2025 (Estimated)Latest JAGX, MLND, HOTH, TNXP, and NEOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025JAGXJaguar Animal Health-$7.13N/AN/AN/A$3.27 millionN/A8/8/2025N/AHOTHHoth Therapeutics-$0.27N/AN/AN/AN/AN/A5/15/2025Q1 2025JAGXJaguar Animal Health-$18.50-$16.70+$1.80-$16.70$3.29 million$3.50 million5/12/2025Q1 2025HOTHHoth Therapeutics-$0.34-$0.27+$0.07-$0.27N/AN/A5/12/2025Q1 2025TNXPTonix Pharmaceuticals-$3.23-$2.84+$0.39-$2.84$2.55 million$2.43 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHOTHHoth TherapeuticsN/AN/AN/AN/AN/AJAGXJaguar Animal HealthN/AN/AN/AN/AN/AMLNDMillendo TherapeuticsN/AN/AN/AN/AN/ANEOSNeos TherapeuticsN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHOTHHoth TherapeuticsN/A15.0915.08JAGXJaguar Animal Health22.201.080.70MLNDMillendo TherapeuticsN/A6.396.39NEOSNeos TherapeuticsN/A0.660.53TNXPTonix PharmaceuticalsN/A12.3111.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHOTHHoth Therapeutics7.08%JAGXJaguar Animal Health12.04%MLNDMillendo TherapeuticsN/ANEOSNeos Therapeutics33.13%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipHOTHHoth Therapeutics6.92%JAGXJaguar Animal Health0.38%MLNDMillendo TherapeuticsN/ANEOSNeos Therapeutics3.80%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHOTHHoth Therapeutics413.21 million12.30 millionNot OptionableJAGXJaguar Animal Health501.02 million1.01 millionNo DataMLNDMillendo Therapeutics1219.04 millionN/ANot OptionableNEOSNeos Therapeutics21349.76 millionN/AOptionableTNXPTonix Pharmaceuticals507.36 million7.36 millionNot OptionableJAGX, MLND, HOTH, TNXP, and NEOS HeadlinesRecent News About These CompaniesTonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 5.8% - Time to Sell?July 11, 2025 | marketbeat.comTonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine ResultsJuly 10, 2025 | msn.comTonix up after peer reviewed data for pain therapy and new data for mpox vaccineJuly 10, 2025 | msn.comTonix Pharmaceuticals (TNXP) Surges 10% on Phase 3 Data ReleaseJuly 10, 2025 | gurufocus.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 11.4% - Should You Buy?July 10, 2025 | marketbeat.comTonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate ...July 10, 2025 | gurufocus.comTonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate ...July 10, 2025 | gurufocus.comTonix Pharmaceuticals (TNXP) Unveils Promising TNX-801 Vaccine Data | TNXP Stock NewsJuly 10, 2025 | gurufocus.comTonix Pharma Unveils Promising TNX-801 Vaccine FindingsJuly 10, 2025 | tipranks.comTonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025July 10, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading 6.5% Higher - Here's WhyJuly 9, 2025 | marketbeat.comTonix Pharma Publishes Phase 3 Trial ResultsJuly 9, 2025 | tipranks.comTonix Pharmaceuticals Announces Publication of Positive Phase 3 RESILIENT Trial Data for TNX-102 SL in Fibromyalgia ManagementJuly 9, 2025 | quiverquant.comQTonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain MedicineJuly 9, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 2.5% - Here's WhyJuly 7, 2025 | marketbeat.comTonix Pharmaceuticals Announces Efficacy and Safety of Single-Dose TNX-801 Vaccine Against MonkeypoxJuly 7, 2025 | quiverquant.comQTonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025July 7, 2025 | globenewswire.comTNXP Tonix Pharmaceuticals Holding Corp. - Seeking AlphaJuly 4, 2025 | seekingalpha.comTonix Pharmaceuticals' Combination Therapy of mTNX-1700 and Anti-PD1 Antibody Shows Promising Results in Gastric Cancer ModelsJuly 2, 2025 | quiverquant.comQTonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal ModelsJuly 2, 2025 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.7% - Here's WhyJuly 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJAGX, MLND, HOTH, TNXP, and NEOS Company DescriptionsHoth Therapeutics NASDAQ:HOTH$1.40 -0.04 (-2.45%) As of 12:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Jaguar Animal Health NASDAQ:JAGX$2.40 +0.02 (+0.63%) As of 12:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.Millendo Therapeutics NASDAQ:MLNDAs of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.Neos Therapeutics NASDAQ:NEOSNeos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.Tonix Pharmaceuticals NASDAQ:TNXP$46.32 +3.54 (+8.27%) As of 12:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVDA Greenlight: China H20 Sales Spark 50% Rally Potential New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Insider Selling Hits Market Leaders—Should You Be Worried? MP Materials Stock Booms on New Government Positioning Tilray Shares Blazing: What's Behind the 55% Rally This Month? Will Dollar Tree Break Out After a New $2.5 Billion Buyback? The Reason Analysts Are Bullish on Bloom Energy Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
